Evidence map›Paper›PMID 29603546›Full record

Trial reportDiabetes, obesity & metabolism2018

Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

Salvatore Carbone, Justin M Canada, Hayley E Billingsley, Dinesh Kadariya, Dave L Dixon, Cory R Trankle, Leo F Buckley, Roshanak Markley, Chau Vo, Horacio Medina de Chazal and 4 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02862067 (SGLT2 Inhibition in Diabetic Patients With Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02862067 completednot on this map

SGLT2 Inhibition in Diabetic Patients With Heart Failure With Reduced Ejection Fraction

TypeobservationalSponsorVirginia Commonwealth UniversityRan2016 to 2018Enrolled18ConditionsDiabetes Mellitus, Type 2, Heart Failure, SystolicArmsAssessment of cardiorespiratory fitness
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Salvatore CarboneDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0002-8163-0527
Justin M CanadaDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Hayley E BillingsleyDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Dinesh KadariyaDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Dave L DixonDepartment of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, Virginia.
Cory R TrankleDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Leo F BuckleyDivision of Cardiovascular Medicine and Department of Pharmacy Service, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0003-1570-1486
Roshanak MarkleyDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Chau VoDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Horacio Medina de ChazalDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Sanah ChristopherDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Raffaella BuzzettiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Benjamin W Van TassellDepartment of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, Virginia.
Antonio AbbateDepartment of Internal Medicine, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Virginia Commonwealth University · USBrigham and Women's Hospital · USSapienza University of Rome · IT

Funding

Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
NCATS NIH HHS UL1 TR000058
6 · The paper itself

Abstract

The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO

Indexed as

Cardiorespiratory FitnessBenzhydryl CompoundsBody Mass IndexCohort StudiesDiabetes Mellitus, Type 2Diabetic CardiomyopathiesDrug InteractionsFemaleGlucosidesHeartHeart FailureHumansMaleMiddle AgedObesityOxygen ConsumptionBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsSodium Potassium Chloride Symporter Inhibitorscardiorespiratory fitnessdiureticsempagliflozinheart failureSGLT2 inhibitors

Identifiers

PMID29603546
PMCPMC6043379
OpenAlexW2795301404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.